Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Gwenaelle Gravis

Praticien Hospitalier Spécialiste Oncologie; Head of the onco-urology (since 2001) , Head of the outpatient unit (2002-2018) , Reviewer for the Clinical Research protocol (since 2017)

Institut Paoli-Calmettes

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (8)

jean-michel hannoun-levi

Professeur

Université Côte d'Azur

FRANCE

View details

Adam Sharp

Team Leader

Institute of Cancer Research

UNITED KINGDOM

View details

Bertrand TOMBAL

Chairman

Université catholique de Louvain

BELGIUM

View details

Benoit Blanchet

FRANCE

View details

Alicja Puszkiel

Université Paris Cité

FRANCE

View details

Yohann Loriot

Institut Gustave Roussy

FRANCE

View details

John Haanen

Chair of Translational Immunotherapy of Cancer

Leiden University Medical Center

NETHERLANDS

View details

Xavier Maldonado

Head of Department

Hospital Universitari Vall d'Hebron

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gwenaelle Gravis

Research Interests

Explore related searches

Articles (20)

Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review

Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study

A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC).

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study

De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?

A randomised, multicentre, phase II trial of active surveillance with or without six months of apalutamide for prostate cancer.

Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum

CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Thera py in Patients with Metastatic Renal Cell Carcinoma

Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods

Pathophysiological rationale and management of anxio-depressive syndrome among cancer patients

Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12

The LuxAR-02 phase II study of luxdegalutamide in combination with [<SUP>177</SUP>Lu]Lu-PSMA-617 in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration resistant prostate cancer (mCRPC).

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial

Chemotherapy use in triplet approach for metastatic hormone-sensitive prostate cancer: French practice survey and expert opinion.

BTN2A1 acquisition through trogocytosis enhances Vy9VS2 T cell cytotoxicity against autologous and cancer cells

Can bladder MRI avoid systematic second TURBT for patients with high-risk NMIBC?

Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n˚157)

Effect of a letter of condolence proposing a post-mortem consultation to the relatives of cancer patients on anxiety, depression and grief: Results of a multicenter randomized study.

Improving transparency and empowerment for cancer patients by accessing their full online personal medical records

Collaborators (8)

jean-michel hannoun-levi

Adam Sharp

Bertrand TOMBAL

Benoit Blanchet

Alicja Puszkiel

Yohann Loriot

John Haanen

Xavier Maldonado

Make your next move.